We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ACAXU market cap is 34.14M. The company's latest EPS is USD 0.0691 and P/E is 19.10.
Quarter End | Aug 2022 | Nov 2022 | Feb 2023 | May 2023 | Aug 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -213k | -347k | -153k | -237k | -396k |
Net Income | 77k | 99k | 561k | 395k | -176k |
Year End 30 November 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 |
Operating Income | -689k | -1.25M |
Net Income | 114k | 549k |
Quarter End | Aug 2022 | Nov 2022 | Feb 2023 | May 2023 | Aug 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Total Assets | 89.07M | 89.3M | 89.91M | 21.95M | 22.08M |
Total Liabilities | 3.27M | 3.4M | 3.45M | 3.44M | 3.75M |
Total Equity | -1.47M | -2.03M | -2.13M | -1.57M | -2.05M |
Year End 30 November 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Total Assets | 89.3M | 21.96M |
Total Liabilities | 3.4M | 3.86M |
Total Equity | -2.03M | -2.36M |
Quarter End | Aug 2022 | Nov 2022 | Feb 2023 | May 2023 | Aug 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | ||||
Operating | -186k | -514k | -335k | -815k | -1.29M |
Investing | -87.12M | -87.13M | N/A | 69.1M | 69.07M |
Financing | 88.76M | 88.76M | 13k | -68.24M | -68.14M |
Year End 30 November 2023 | 2022 | 2023 |
---|---|---|
USD (US$) | USD (US$) | |
Operating | -514k | -1.52M |
Investing | -87.13M | 69.08M |
Financing | 88.76M | -68.15M |
Market Cap | 34.14M |
Price to Earnings Ratio | 19.10 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 17.89 |
Price to Book Ratio | 0.58 |
Dividend Yield | - |
Shares Outstanding | 7.94M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | -59.05% |
52 Week High | 28.01 |
52 Week Low | 4.00 |
Spread (Intraday) | 5.7 (57%) |
Company Name | Alset Capital Acquisition Corporation |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.hwhintl.com |
Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions